Acute massive pulmonary embolism has a high mortality rate. Fatal haemodynamic deterioration is caused by an acute increase in pulmonary vascular resistance. Traditionally, the degree of mechanical obstruction of the pulmonary vasculature by the embolic thrombus is considered to be the major determinant of this increase in right ventricular afterload. However, there is evidence to suggest that another factor plays an important role, since there is a marked discrepancy between the haemodynamic manifestations of acute pulmonary embolism and the degree of mechanical obstruction. Historic studies indicate that this discrepancy is largely explained by pulmonary vasoconstriction caused by vasoactive mediators, released mainly by activated platelets. Thromboxane-A and serotonin are probably the 2 two most important pulmonary vasoconstrictors in this context. Antagonising their effects dramatically increases tolerance to experimental pulmonary embolism in animals. In humans, this concept should eventually find its way into clinical practice. In the future, acute massive pulmonary embolism could be treated with antagonists to pulmonary vasoconstrictors, or with direct pulmonary vasodilators. 
Introduction
after gain in surgical experience for thrombectomy, and after the introduction of thrombolytic therapy and catheter Pulmonary embolism (PE) is a frequently encountered embolectomy, estimate mortality from PE in haemodynamdisorder, especially in hospital settings. Estimations for the ically unstable patients at between 23 and 38% [10, 11] . US are that PE occurs in about 600 000 patients annually, Death due to PE is often instantaneous (within minutes), and causes 50 000-200 000 deaths [1] [2] [3] . PE is held and of all fatal cases, up to 90% succumb within 2 h after responsible for -or at least contributes to -up to 15% the onset of symptoms [7, 9, 12] . The rapid clinical deterioof total in-hospital mortality [1, 4, 5] . PE often goes unreration, combined with the fact that the diagnosis of PE is cognised, as reports indicate that only in about one third of frequently missed, both contribute to the fact that only a all patients that died from PE was the correct diagnosis minority (an estimated 6.5%) of PE deaths occur in suspected antemortem [6, 7] . Hospital mortality rates patients who are actually treated for PE [1] . caused by clinically apparent PE are 30% for untreated Acute right-sided heart failure due to increased pulmonpatients, and around 2.5% for those receiving up-to-date ary vascular resistance (PVR) is the prime cause of death treatment [8] . For acute massive PE with haemodynamic in PE [13] . The rapid rise in afterload causes dilatation of instability, the 1-h mortality rate approached 70% in the the right ventricle, which, together with systemic hypotenprethrombolysis era [9] . More recent studies, performed sion, compromises coronary perfusion, causing ischaemia and sometimes even myocardial infarction. The septal shift resulting from right ventricle dilatation further reduces left
Abbreviations: COX, cyclooxygenase; NO, nitric oxide; PAP, pulmonventricular preload, and the patient enters a 'vicious cycle' ary artery pressure; PE, pulmonary embolism; PG, prostaglandin; PVR, of acute right sided heart failure [14, 15] . Traditionally, the pulmonary vascular resistance; TxA , thromboxane-A degree of mechanical obstruction of the pulmonary vascuarachidonic acid metabolism [26] . There are two classical lar bed was considered to be the only determinant of the metabolic routes for arachidonic acid metabolism. One is PVR increase in PE. Over the years, however, a number of the cyclooxygenase (COX) pathway, in which, through the observations have challenged this concept. Firstly, several enzymatic action of COX, arachidonic acid is converted to studies have shown that the correlation between the degree endoperoxides prostaglandin-G2 (PGG ) and PGH . These 2 2 of mechanical obstruction and the haemodynamic manitwo substances are intermediates in the formation of the festations of PE is either absent, or poor at best [16] [17] [18] .
biologically active prostaglandins: PGD , PGE , PGF , 2 
a
Furthermore, bringing about a strictly mechanical obstruc-PGI (prostacyclin), and, through the action of thrombox-2 tion by cross-clamping the left or right pulmonary artery ane synthase, TxA . The alternative metabolic pathway for 2 during a surgical procedure, or by unilateral balloon arachidonic acid is the 5-lipoxygenase pathway, which occlusion, causes only a modest rise in pulmonary artery results in the synthesis of leukotrienes and 5-hydroxypressure (PAP), and almost never results in right-sided eicosatetraenoic acid. The lipoxygenase pathway is probaheart failure [17, 19, 20] , whereas PE with obstruction of bly also activated after PE, but does not directly contribute only 625% of the pulmonary vascular tree can cause to the rise in PVR [27] . For a more detailed discussion of marked pulmonary hypertension [21] . Also, major PE can arachidonic acid metabolism and thromboxane signal be found during autopsy in patients who never had any transduction, the reader is referred to recent literature clinical manifestations of PE [1, 6] . As early as in the [28] [29] [30] . TxA is produced primarily in platelets in 2 1940s and 1950s, it was acknowledged that vasoconstricresponse to platelet activation. Other potential sources of tion of the pulmonary vascular bed is present in PE. Case
TxA production include the vascular endothelium and 2 reports from this period showed that stellate ganglion circulating monocytes, but these sources are quantitatively blockade, performed on the symptomatic side in nonless important than platelets. The main physiologic role of heparinised patients with PE, reduced cyanosis, dyspnea, TxA is to enhance platelet aggregation and to cause 2 and circulatory shock [22, 23] . Stellate ganglion blockade vasoconstriction, both in the interest of effective haemoscan markedly attenuate pulmonary vasoconstriction [24] .
tasis. The vasoconstrictive effect of TxA applies to both 2 Cross-transfusion experiments in sheep demonstrated inthe systemic and the pulmonary vascular system [26] . creases in PAP in the non-embolised sheep, approximately TxA production after acute PE has been studied using 2 20-30 s after embolisation of its pairmate, providing measurements of its stable degradation product TxB . It 2 support for a role of circulating vasoconstrictive mediators should be stressed that TxB measurements are not as 2 [25] . After the identification of several candidate vasoacprecise in assessing TxA production as some of the more 2 tive mediators, further evidence for their role in PE came recently developed techniques, like analysis of plasma from animal experiments in which these mediators were 11-dehydro-TxB and urinary 11-dehydro-TxB or 2,3-2 2 pharmacologically antagonised. In these studies, which dinor-TxB [26] . Except for one study in experimental fat 2 will be discussed below, animals who were treated with embolism [31] , these more recently developed analytical such mediator antagonists could survive massive PE techniques have, to my knowledge, not been employed in without marked haemodynamic disturbances, whereas the the context of acute PE. majority of control animals died or developed severe Several studies have shown that increased production of circulatory shock.
TxA takes place in PE, especially in the early stages (first 2 In recent reviews and treatment recommendations for 10-30 min) [32, 33] . The degree of TxA production has 2 PE, the focus is exclusively on interventions aimed at been shown to correlate with the risk of mortality in removing the mechanical obstruction. Hence, it is necesexperimentally induced PE in animals [32] . Also, the surge sary to reassess the potentially important role of pulmonary in TxA production is related to the respiratory response to 2 vasoconstriction in the increase in PVR after acute PE. acute PE [34] . [34] [35] [36] , or microsphere / glass bead embolisation [37] [38] [39] . COX inhibition was accom-
Vasoactive mediators in pulmonary embolism
plished by pretreatment of the animals with indomethacin [34, 37] , ibuprofen [38] , meclofenamate [38, 39] , or 2.1. Thromboxane-A acetylsalicylic acid [35] . These studies showed a markedly 2 attenuated haemodynamic response in the animals preThere is strong evidence that thromboxane-A (TxA ), a treated with a COX inhibitor compared to controls. The 2 2 strong vasoconstrictor, plays a role in the pulmonary rise in PAP after acute PE was about 40-60% of that response to acute PE. TxA is one of the end products of observed in control animals [35, [37] [38] [39] . Also, the increase in PVR following an arachidonic acid or thrombin infusion The role of serotonin in pulmonary vasoconstriction is virtually abolished by pretreatment with a COX inhibitor after PE has been recognised since the 1960s. Infusion of [35, 40] . The observation that this beneficial effect of COX serotonin in dogs can accurately simulate signs and inhibition is not accompanied by less platelet sequestration symptoms of PE [53, 54] . Also, depletion of platelet in the lungs suggests that it is the antagonism of the serotonin by reserpine decreases vascular responsiveness to vasoconstrictive effect of TxA , rather than of its platelet PE [55, 56] , whereas pretreatment with a monoamine 2 aggregating effect, that explains the attenuation of the oxidase inhibitor which increases platelet serotonin conincrease in PVR [41] . The effect of COX inhibitors in tent, aggravates the haemodynamic response to PE [57] . humans with PE has never been studied. The possible Serum serotonin concentrations increase in animals after reasons for this are outlined in the discussion. It is, experimental induction of haemodynamically significant however, worth mentioning that ibuprofen has been used PE [58] . successfully to lower PAP in patients with adult respiratory Several animal studies with serotonin antagonists have distress syndrome, presumably also through an inhibitory been performed. One of the most studied antagonists is effect on TxA production [42] .
methysergide. In various models of autologous-clot-in- 2 Note that COX inhibition is a relatively non-specific duced PE, methysergide markedly attenuated the haemoway of inhibiting TxA synthesis, since the production of dynamic response to PE [35, 36, 57] . Another serotonin 2 the prostaglandins is also impaired. This effect may antagonist, cyproheptadine, could completely block the rise contribute to some of the effects of COX inhibitors other in PVR after autologous clot infusion in dogs [58] . than reduction of pulmonary vasoconstriction. For examSerotonin antagonists have also shown a beneficial effect ple, COX inhibitors may also reduce PE-related hypoxon gas exchange after PE [59] . When both a COX inhibitor aemia, probably because TxA and prostaglandins, by their and a serotonin antagonist (methysergide) were used, the 2 combined effects on vasal and bronchial tonus, play a role partial attenuation of the rise in PVR seen with methyserin PE-related ventilation-perfusion mismatch [34, 43] . gide alone was replaced by an almost complete abolishOther effects of COX inhibitors in animal PE models ment of the haemodynamic response to autologous clot include reduction of pulmonary edema [37, 40] , and better infusion [35] . Also, the combination of a TxA and a 2 preservation of myocardial contractility, possibly by reducserotonin antagonist can dramatically reduce the mortality ing circulating negative inotropic prostaglandins [33] .
rate from experimentally induced massive PE in rabbits More specific TxA antagonists include TxA synthase from 55 to 0% [36] . In humans, there is no experience with 2 2 inhibitors (like dazoxiben and related imidazol derivaserotonin blockers in the setting of acute PE, except for tives), TxA receptors blockers (daltroban, vapiprost) and ketanserin. Ketanserin inhibits serotonin at serotonin-type-2 picotamide, which is both a TxA synthase inhibitor and a 2 receptor sites [60, 61] , which are located on platelets and 2
TxA receptor antagonist. These agents could theoretically on vascular and bronchial smooth muscle [62, 63] . On the 2 perform better than COX inhibitors, since these do not other hand, ketanserin also has a1-adrenergic blocking inhibit prostacyclin synthesis, but rather cause a shift in properties, which are responsible for its systemic vasodilaendoperoxide metabolism towards increased formation of tory effect [61] . As such, it is used as a systemic vasodilaprostacyclin [44] [45] [46] . On the other hand, this shift also tor in the treatment of hypertension, and its role in PE will stimulates PGF synthesis, which may overrule the be discussed below (see under Vasodilator therapy). 2a beneficial effects of TxA inhibition and prostacyclin Platelets are the major source of TxA and serotonin 2 2 stimulation [47] . Some studies of experimental PE have production in PE, but exactly which platelets are responbeen performed using these drugs, and the results are sible is unclear. The embolus itself is a fibrin-rich clot, and largely, but not unequivocally [48] , in accordance with the degree to which the relatively limited number of those of the COX inhibition studies [34, 44, 49] .
platelets embedded in this clot can still contribute to the release of TxA and serotonin is questionable. Microscopic 2 2.2. Serotonin studies have however shown that the surface of a clot that has caused PE is covered with freshly aggregated platelets. Serotonin (5-hydroxytryptamine) plays a role in various Thrombin-platelet interaction at the clot surface is pretypes of primary and secondary pulmonary hypertension sumably of key importance in this platelet activation. The [50] . It can be produced by gastrointestinal enteropossible role of other platelet activators, such as ADP and chromaffin cells, serotonergic neurons, pulmonary neuroplatelet-activating factor, is unknown. Also, we do not endocrine cells, and by activated platelets. On a molar know to what extent local endothelial cell activation basis, serotonin is the single most powerful pulmonary stimulates platelet aggregation. In any case, it is likely that vasoconstrictor known, whereas in the systemic circulathe platelets aggregated at the surface of the embolic clot tion, it causes vasodilation [51] . A detailed discussion of are largely responsible for mediator release [57, 64] . The the wide variety of serotonin receptors is outside the scope number of circulating platelets prior to the experimental of this review [50] . In addition to effects on vascular tone, induction of PE is related to the mortality rate [65] . The serotonin has positive inotropic properties [52] .
rise in TxA and serotonin in serum corresponds closely to the post-PE fall in platelet counts, suggesting that these mechanism is overruled by the abundant presence of mediators originate from aggregated platelets [34, 58] .
vasoactive mediators [71] . If marked hypoxaemia is presThus, platelets that were circulating prior to PE are ent in PE, supplemental oxygen administration has, howprobably the major source of production of vasoconstricever, been reported to cause a reduction in PVR [72] . tive mediators after PE. This argumentation applies both to TxA and to serotonin. A decrease in serotonin content in 2. Endothelin is produced by the vascular endothelium, and release from platelets, and inhibits pulmonary endothelial causes marked and sustained vasoconstriction. There are uptake of serotonin [58] . In addition, it may have bronseveral subtypes, of which endothelin-1 is known in chodilating [73] and positive inotropic actions [74] . Prosparticular for its ability to cause pulmonary hypertension tacyclin (measured by its stable metabolite 6-keto-PGF ) 1a [50] . Few data are available to define the role of is released into the pulmonary circulation in response to endothelin-1 in the vasoconstrictive response to PE. A PE, and appears to reach its peak levels some time after the recent study of air emboli in isolated rabbit lungs showed peak in TxA and serotonin release [32] . Blocking pros-2 that the endothelin type-A receptor antagonist LU-135252 tacyclin synthesis or action in this phase can result in significantly reduced the short term increase in PAP.
haemodynamic deterioration (see Discussion). The theraInterestingly, this endothelin antagonist also reduced the peutic potential of using prostacyclin as a pulmonary increase in TxB levels that were observed in the control vasodilator will be discussed below. animals. The pressure-time curve for the endothelin The extent to which other vasodilatory mediators (like receptor antagonist was similar to the curve obtained after PGE ) play a role in attenuating the response to pulmonary 1 pretreatment with diclofenac, with no evidence of an vasoconstrictors is undetermined. It is possible that inadditive effect of both drugs [67] . These and previous [68] creased nitric oxide (NO) synthesis occurs after PE, but data thus suggest that endothelin-1 may exert its pulmonthis has not been studied. Other endothelium-derived ary vasoconstrictive effect through activation of TxA vasodilators also deserve further study. Possibly, increased 2 generation. Release of endothelin, or rather of its precursor production of atrial natriuretic peptide also attenuates big-endothelin, from the lungs after PE has another pulmonary vasoconstriction after PE [75] . unfavourable effect in the form of coronary vasoconstriction, which may contribute to cardiodepression [69] .
Prostaglandin F (PGF ) is also released following 3. Vasodilator therapy in pulmonary embolism 2a 2a
PE, and contributes to pulmonary vasoconstriction [47] . Its precise role is unknown, but is probably less important In addition to specific antagonists of vasoconstrictive than that of the previously discussed vasoconstrictors. The mediators, vasodilators may offer therapeutic benefit in same is true for prostaglandins-H , -D , -E and haemodynamically unstable patients with PE. The main
leukotriene-D , which are all pulmonary vasoconstrictors, concern, however, is the lack of specificity of these drugs 4 and whose role in acute PE remains to be determined. In for the pulmonary vasculature. Arterial hypotension can be addition, histamine may also add to pulmonary vasoconexpected to worsen, certainly if the reduction in systemic striction, as antihistamines have been shown to moderately vascular resistance exceeds that of PVR. Vasodilators that attenuate the rise in PVR after microembolisation in dogs specifically cause pulmonary vasodilation are not avail- [39] .
able. One solution would be the intravenous administration One final possible contributor to pulmonary vasoconof vasodilators with a high pulmonary extraction rate, like striction needs to be addressed, namely hypoxic pulmonary the vasodilatory prostaglandins [76] . Alternatively, vasodivasoconstriction. Hypoxaemia in PE is variably present, lators may be given locally by inhalation. The effects of and certainly does not appear to be a prerequisite for different vasodilators in animals and in humans with PE haemodynamic instability. Its pathogenesis is complex will be discussed, starting with two 'natural' vasodilators: [70] , and is outside the scope of this review. Probably, prostacyclin and NO. hypoxic pulmonary vasoconstriction is not an important contributor to the increase in PVR. Studies have shown 3.1. Prostacyclin that the hypoxic pulmonary vasoconstrictive response is blunted in patients with PE, conceivably because its Prostacyclin is, as discussed above, a physiological vasodilatory mediator in PE, but it is also available as a that, in humans, serotonin-type-1 rather than type-2 retherapeutic agent. Its vasodilatory action is, however, not ceptors mediate this response [50] . The serotonin-type-2 at all specific for the pulmonary vessels. Intravenous blocking effects of ketanserin may still explain its pulmonprostacyclin has been used for the treatment of haemoary vasodilatory effect by reduction of serotonin-mediated dynamically unstable dogs with autologous clot PE platelet activation with subsequent release of vasoconstric- [34, 77] . The fall in systemic blood pressure in these tive mediators [53, 63] . However, ketanserin also has other, experiments approached or slightly outweighed the fall in potentially unfavourable, effects. It has a1 adrenergic PAP, whereas gas exchange parameters improved. Prosblocking properties, which are responsible for the systemic tacyclin can also be administered by inhalation, but the vasodilation seen with this drug [52, 95] . In addition, literature regarding the effects of inhaled prostacyclin is ketanserin appears to block the positive inotropic effect of limited. In a canine model of glass bead microembolisation serotonin [54] . Several animals studies have assessed the and oleic acid pulmonary edema, prostacyclin inhalation effects of ketanserin in PE models. In a model of autologwas ineffective [78] . A case report described a beneficial ous blood clot infusion in dogs, pretreatment with ketaneffect of inhaled prostacyclin in a patient with massive PE, serin markedly attenuated the rise in PVR from 5 to 120 in whom PAP decreased by 15 mmHg without a fall in min after PE, and also inhibited both the post-PE fall in systemic blood pressure, and oxygenation improved markcirculating platelets, arterial hypoxaemia, and pulmonary edly, but this effect was transient [79] .
edema [53] . Unfortunately, the effects of ketanserin on systemic haemodynamics were not reported in this study.
Nitric oxide
In an earlier, similar dog study, post-PE administration of ketanserin decreases PAP by 50%, as opposed to only a NO is a potent endothelium-derived vasodilator. Inhaled 10% drop in systemic blood pressure, and also improved NO has been shown to cause selective pulmonary vasodigas exchange parameters [66] . In humans, a marginally lation, and can be effective in primary and secondary beneficial effect of ketanserin has been suggested by Huet pulmonary hypertension [80] , as well as in adult respiratoet al., who described the haemodynamic response in ten ry distress syndrome, in which it improves oxygenation by patients with severe PE to 14 mg of ketanserin, adminisreducing ventilation-perfusion mismatching [81] . Not only tered during the course of 1 h [96] . Mean PAP (212%) and is inhaled NO a vasodilator, it also has platelet-inhibitory PVR (216%) decreased only slightly more than systemic properties that could be beneficial in terms of reducing blood pressure (29%) and systemic vascular resistance platelet-derived vasoconstrictive mediators [82] [83] [84] . Sever-(210%), whereas cardiac output remained unchanged. al animal studies of acute and chronic pulmonary hypertenAlso, oxygenation improved slightly with ketanserin in this sion resulting from experimentally induced PE have shown study. that NO inhalation can markedly reduce PVR without adversely affecting systemic haemodynamics or oxygen-3.4. Hydralazine ation [85] [86] [87] [88] . In humans, several case reports have been published, which invariably report a marked haemodynamThe direct vasodilator hydralazine has been the subject ic improvement after NO inhalation [89] [90] [91] . Systemic of several animal studies. In a canine model of autologous blood pressure, as expected, was not adversely affected by blood clot PE, hydralazine caused a 41% reduction in PVR NO inhalation in any of these cases. One case was reported and a doubling of cardiac output, at the expense of only a in which NO inhalation resulted in closure of a patent 5% reduction in systemic blood pressure, and a 31% rise in foramen ovale in a patient with PE [92] . Inhaled NO was intrapulmonary shunt fraction, without affecting arterial also reported to be effective when an increased PAP partial oxygen pressure [97] . The effect of hydralazine on persisted after surgically successful thrombectomy [93] .
systemic blood pressure appears to be more dose-depenFinally, in one recently described case, NO inhalation was dent than the effect on PVR [97, 98] . In humans, the used during cardiopulmonary resuscitation for massive PE, experience is limited to case reports. A marked improveand was followed by restoration of spontaneous circulation ment of PVR and cardiac index in response to oral [90] . NO has been reported to cause moderate oxygen hydralazine was reported in an elderly woman with desaturation in a single case report [94] , possibly by extensive bilateral PE at the cost of only a minor reduction causing an increase in ventilation-perfusion mismatch, or in systemic blood pressure [99] . Hydralazine theoretically by opening previously unperfused shunt units. In all other has additional benefits in that it is a weak inhibitor of reported cases, such a side effect was not observed.
TxA synthase [100] , and has positive inotropic properties actions. Amrinone has shown excellent results in a canine 4. Other treatments that may influence pulmonary model of autologous blood clot PE, with a 20% fall in PAP vascular tone and an almost complete recovery of severe systemic hypotension [102] . There is one case report of a patient
The cornerstone of current PE treatment is anticoagulawith haemodynamic instability due to PE, whose haemotion with heparin in haemodynamically stable patients, and dynamic and gas exchange parameters all improved after fibrinolytic therapy in patients presenting with haemoamrinone therapy [103] . Apart from amrinone, other dynamic instability or respiratory failure. Traditionally, the phosphodiesterase-III inhibitors also improved haemodyeffect of these therapies is considered to be based on namic instability in dogs with experimental PE, with inhibition of clot growth (heparin), enabling endogenous evidence of a more marked vasodilatory effect on the fibrinolysis to occur, or on drug-induced fibrinolysis pulmonary than on systemic vasculature [104, 105] . Final-(streptokinase, urokinase, recombinant tissue plasminogen ly, some phosphodiesterase inhibitors have been shown to activator). It is possible, however, that these therapies also inhibit platelet aggregation, which may represent an addireduce pulmonary vasoconstriction. Anticoagulation with tional benefit [106] .
heparin inhibits thrombin and reduces thrombin formation, thereby interrupting thrombin-induced platelet activation, 3.6. Other vasodilators which may reduce the release of platelet-derived vasoconstrictive mediators. The importance of thrombin-platelet The experience with isoproterenol in experimental PE in interaction in the setting of PE was demonstrated already animals or clinically in humans is generally disappointing in 1968, when Gurewich et al. showed that pretreatment [107, 108] . Nitroglycerine causes both venous and arterial with heparin blunted, in a dose-dependent fashion, the vasodilation, but the effect on the venous system is more haemodynamic response to clot-induced PE in rabbits [57] . pronounced. In the setting of PE, it has been shown to Later, this effect was also shown in a canine microembolireduce PVR at the cost of a relatively mild decrease in sation model [113] . Note that, in haemodynamically systemic blood pressure, but this effect required substantial unstable PE patients, this effect of heparin represents a intravenous volume loading to compensate for increased theoretical benefit of an intravenous bolus of heparin intravascular volume [109] . Nitroprusside is an ultra short immediately after the diagnosis of PE, as opposed to acting vasodilator with less venous vasodilation compared treatment with subcutaneous low-molecular-weight to nitroglycerine. Its effect in experimental PE has been heparin. In fact, in the early days of heparin treatment, studied only in comparative studies with other vasodilatwhen 15 000 U were administered intravenously, the ors, discussed below. Finally, captopril was shown to be recommendation was to do so immediately after the ineffective in a canine microembolisation model [110] . diagnosis of PE, because of an immediate favourable The role of other vasodilators in PE has not been studied.
clinical response to this bolus injection [114] . It is also of note that heparin may cause modest endothelium-depen-3.7. Comparative studies dent vasodilation [115, 116] , and may preserve endothelial vasodilatory function after ischaemic injury [117] . Comparative studies of vasodilators in PE are only How fibrinolytic therapy reduces the release of vasoacavailable for animals. In one study, nitroprusside, hytive mediators is more difficult to understand, but two dralazine and PGE , given in fixed doses, were compared observations suggest that these drugs may do more than 1 in a canine model of autologous blood clot PE [98] . PGE just cause clot lysis. Firstly, a haemodynamic response to 1 was not effective in reducing PAP, whereas nitroprusside these agents is often seen earlier than one would expect and hydralazine both decreased PAP by 19%, at the substantial clot lysis to occur. Secondly, and most imexpense of a 44% reduction in systemic blood pressure.
portantly, the haemodynamic improvement after thromNeither nitroprusside nor hydralazine changed ventilationbolytic therapy correlates poorly, at least in some studies, perfusion distributions. Hydralazine and nitroprusside were to the angiographically determined resolution of mechanialso compared in another canine autologous blood clot cal vascular obstruction [118] . model [111] . In this study, hydralazine was superior to Finally, the effect of anti-platelet drugs other than COXnitroprusside, which, in contrast to hydralazine, did not inhibitors or specific TxA inhibitors on haemodynamic 2 reduce PVR or increase cardiac output. Finally, hymanifestations of PE is unknown, but certainly not without dralazine, nitroglycerin, and PGE were compared in a potential clinical relevance. 1 canine model of acute PE by autologous muscle injection. Again, hydralazine was superior to both other drugs in its effect on PVR, but even more so in its effect on cardiac 5. Discussion performance [112] .
The treatment of PE with positive inotropic and vasoBased on the evidence presented, it is plausible that pressor agents is outside the scope of this paper. The pulmonary vasoconstriction, caused by the release of reader is referred to another review [107] .
predominantly vasoconstrictive mediators, is an important contributor to the increase in PVR in patients with acute TxA synthesis inhibition is much stronger compared to 2 PE. As discussed, most patients who succumb to PE do so prostacyclin synthesis inhibition [26] . Unfortunately, no within minutes to few hours after the onset of symptoms.
animal studies have been performed comparing the effects This is not surprising considering the time-pressure curves of low-and high-dose COX inhibitors. The second imof experimentally induced PE, which invariably show a portant limitation of the use of COX inhibitors is of course strong initial rise in PAP, followed by a slow-decrease or a the risk of gastrointestinal bleeding, especially in combinaplateau phase, during which PAP is still higher than tion with anticoagulation or fibrinolytic therapy. baseline, but clearly lower than during the initial 30 to 60
In summary, pretreatment with TxA inhibitors will 2 min [35, 39, 53, 77] . This suggests that pulmonary vasoconattenuate the rise in PVR in the early phase of PE, but striction may be most important in the early stages of PE, could increase PVR in later stages. Since it is the early which may have therapeutic implications in the sense that phase of PE which is often fatal, these agents may still be drugs that antagonise vasoconstrictive mediators could be able to reduce acute mortality. In this respect, the results of most effective if given in the initial phase of haemothe recent Pulmonary Embolism Prevention trial are indynamic instability. The clinical implication of this hytriguing. This large randomised placebo controlled study pothesis is that early treatment of pulmonary vasoconstricshowed that aspirin reduced the incidence of PE after hip tion should be considered in haemodynamically unstable surgery or arthroplasty. However, a sub-analysis indicated patients with PE. However, there are several uncertainties that the incidence of fatal PE was reduced much more than that need to be addressed before clinical use of mediator that of non-fatal PE (risk reduction 58% versus 26%, antagonists or vasodilators can be advocated.
respectively) [122] . It is certainly possible that this differFirstly, the administration of antagonists to TxA and ence reflects a protective effect of pretreatment with 2 serotonin has been studied exclusively in animals. Also, aspirin in patients who develop post-surgery PE. most studies addressed the effects of pretreatment with
As for serotonin antagonists, the animal experiments these antagonists, so the results of these experiments suggest that these agents could be beneficial for human cannot be extrapolated automatically to patients who use, but no human studies have been performed with already have PE. Although one could consider pretreatmethysergide, which appears to work so well in animals, ment in humans, for example in those with very extensive or with any other specific serotonin antagonist, like venous thrombosis, these patients will usually be treated pizotifen. Side effects of serotonin antagonists have not with heparin. As discussed previously, heparin (in suffibeen reported. A paradoxical rise in PVR, as in the case of ciently high doses) impairs coagulation-platelet interac-COX inhibitors, is unlikely to occur with serotonin blocktion. All studies addressing the effect of antagonists of ers. The role of ketanserin as a serotonin antagonist has vasoactive mediators have been in non-heparinised anibeen discussed above. mals, and it is unknown whether TxA or serotonin As discussed, vasodilators may be effective both in the 2 antagonists are at all effective on top of heparin treatment. initial and in the later stages of PE. Clinicians will, Also, the animal experiments often studied very high doses however, intuitively be reluctant to administer vasodilators of vasoconstrictor antagonists (up to 250 mg / kg of to hypotensive patients. The potentially effective approach acetylsalycylic acid, or 3 mg / kg of methysergide). The of combined intravenous vasodilation and aggressive fluid evidence for a similar effect of doses that are closer to filling to compensate for increased intravascular volume those normally used in patients is more discordant has never been specifically studied. However, it has been [34, 37, 119] .
shown that volume expansion alone is safe in patients with Secondly, some antagonists are not without potential PE [123] , and may in fact be more beneficial than side-effects. COX inhibitors in particular have potential vasodilation alone [109] . Of the systemically administered disadvantages. Firstly, they may increase rather than vasodilators studied, ketanserin, one of the phosphodiesdecrease PVR. This effect has been demonstrated in a terase-III inhibitors, or hydralazine may be first choice. canine model of autologous clot PE, in which COX
The most direct way of causing specific pulmonary vasodiinhibitors were used as treatment (1 h after the onset of lation is local administration of a vasodilator. Both pros-PE), rather than as pre-treatment [120] . Another study tacyclin and NO inhalation have been used for this showed that COX inhibitors may potentiate, rather than purpose. The experience with NO is more extensive, and attenuate, the vasopressor response to serotonin [121] . It is almost uniformly positive. Because of its vasodilatory likely that TxA , and possibly also PGF , dominate the action and its antiplatelet activity, NO may aggravate 2 2 a vasomotor response early in the course of PE, and that haemostasis problems, especially in combination with serotonin and prostacyclin are more active in the later anticoagulants or thrombolytic agents. Therefore, it should stages [32, 47] . Thus, the apparently inconsistent effect of be used with caution if haemorrhage accompanies PE, COX-inhibitors in the subacute phase after PE may be which is rarely the case. explained by impairment of prostacyclin production. The
The limitations of this review are predominantly related risk of an adverse response may apply in particular to to the extrapolation of various animals experiments to the higher doses of COX-inhibitors, since in the low doses, human situation. It is known that inter-species variability exists [124] . Also, the models of experimentally induced 
